TAMPA, Fla.--(EON: Enhanced Online News)--Morphogenesis Inc., a Florida corporation with headquarters in Tampa, FL, announces its plans to raise up to $2 million from the sale of its common stock to accredited investors. The company’s Private Placement Memorandum is expected to be available for review later this month.
Morphogenesis Inc. (www.morphogenesis-inc.com) is an 18-year-old, privately-held biotechnology company which conducts ground-breaking research in the rapidly growing cell therapy, biologics and tissue engineering fields.
Morphogenesis has developed, and is primarily focused on, its multi-indication therapeutic cancer vaccine called, ImmuneFx™, which educates the patient’s own immune system to attack tumor cells throughout the body without damaging normal cells or systems.
Several leading authorities project the annual therapeutic cancer vaccine market to expand to $8 billion within the next six years. Experts predict that within the next 10 years, 50 percent of cancer treatments will involve immunotherapy.
Its wholly-owned subsidiary, Veterinary Oncology Services Inc., assists veterinary oncology physicians in providing this non-toxic therapy in a personalized treatment form for many types of cancers in dogs, cats and horses. Because the immune systems and cancers in companion animals and people are essentially the same, it is expected that if and when approved by the FDA, the therapy will prove equally successful in treating multiple human cancers.
For more information, please contact Joseph S. Scanlan, Chief Operating Officer, at firstname.lastname@example.org.
The stock will be offered in minimum purchases of 50,000 shares at a purchase price of $1 per share. Subscribers for the first 500,000 shares will also receive a three year option to purchase additional shares at a purchase price of $1.25 per share.
INVESTOR NOTICES; DEFINITION OF ACCREDITED INVESTOR
This release is not intended to be an offer to sell or the solicitation of an offer to buy securities. Offers will be made only by delivery of a Private Placement Memorandum.
The securities will be sold only to accredited investors, which for natural persons are investors who have a verified annual income of at least $200,000 ($300,000 with spouse) or a verified net worth of at least $1 million without including the value of the investor’s primary residence. Verification of accredited status must be by acceptable third party information.
The securities are being offered in reliance on an exemption from the registration requirements of the Securities Act, and are not required to comply with specific disclosure requirements that apply to registration under the Securities Act.
The Securities and Exchange Commission has not passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials.
The securities are subject to legal restrictions on transfer and resale and investors should not assume they will be able to resell their securities.
Investing in securities involves a high degree of risk, and investors should be able to bear the loss of their investment.
Morphogenesis is an 18-year-old, privately-held biotechnology company which conducts ground-breaking research in the rapidly growing cell therapy, immunotherapy, biologics and tissue engineering fields.